0

Marizomib for Central Nervous System-Multiple Myeloma

Ashraf Badros, Zeba Singh, Binod Dhakal, Young Kwok, Ann MacLaren, Paul Richardson, Mohit Trikha, Parameswaran Hari

Br J Haematol. 2017 Apr;177(2):221-225.

PMID: 28387460

Abstract:

Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. These cases provide the first proof of principle for further exploring marizomib in CNS-MM patients.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP437742342 Marizomib Marizomib 437742-34-2 Price
qrcode